

## 算一算: "MATH+" 挽救了生命

作者: Michael Passwater; 翻譯: 李梅; 審閱: 成長

原文: <http://www.doctoryourself.com/omns/v16n55.shtml#Ref1>

The Chinese translation of this article is made possible by a generous grant from Dr. Bill Grant and from the Cheng Integrative Health.

本文翻譯工作得到 Bill Grant 博士資助及上海成氏健康資助。

(OMNS 2020 年 12 月 23 日)隨著 SARS-CoV-2 大流行進入北美, 5 名經驗豐富的重癥監護醫生組成了“一線 Covid-19 重癥監護聯盟”(FLCCC 聯盟)。這個最初由危重護理醫生 Pierre Kory、G. Umberto Meduri、Jose Iglesias、Joseph Varon 和 Paul Marik 組成的工作組, 過去和現在都致力於發展和完善 Covid-19 治療方案。2017 年, 隨著靜脈注射可的松(皮質醇)、抗壞血酸(維生素 C)和硫胺素(維生素 B1)放進標準的膿毒血癥護理中, Paul Marik 博士對膿毒血癥的治療方面取得了巨大成功, 包括膿毒血癥休克。這被稱為治療膿毒血癥的“HAT”理論, 它是 FLCCC 聯盟抗擊 Covid-19 的起點。鑒於 Covid-19 的複雜性, “HAT”療法迅速擴充為“MATH+”, 用於 Covid-19 住院患者的護理。

M = 甲基強的松龍: 80mg 負荷劑量, 然後 40mg/12h, 至少 7 天, 直到轉出 ICU

A = 抗壞血酸：3 g IV /6h，至少 7 天和/或直到轉出 ICU。

T = 硫胺素：200mg/12h 靜脈滴註，

H = 肝素（低分子量肝素）：皮下注射 1mg /Kg/12h，禁忌除外

+ = 維生素 D3，褪黑素，鋅，鎂，復合維生素 B，阿托伐他汀，法莫替丁，如有需要，可進行血漿置換治療

“如果你正在做的事情不起作用，那就改變你正在做的事情。” (Paul E. Marik

醫學博士)

早期幹預和避免機械通氣也是 2 個關鍵方面。截至 2020 年 7 月，實施 MATH+ 方法的兩家醫院的結果已經完成了同行評審，現在已在網上公布。他們的發現似乎是奇跡。德克薩斯州休斯頓聯合紀念醫療中心的 Joseph Varon 博士的團隊截至 7 月份治療了 140 名住院的 Covid-19 患者，存活率為 95.6%，弗吉尼亞州諾福克森塔拉諾福克綜合醫院的 Paul Marik 博士的團隊治療了 191 名住院的 Covid-19 患者，存活率為 93.9%。不同的地方是，UMMC 在急癱室開始方案，而諾福克綜合醫院在重癱監護室進行。相比之下，美國、英國和中國的其他 461 家沒有使用 MATH+ 方案的醫院公布的生存率從 68%到 84.4%不等。美國疾病控

製與預防中心報告稱，在 11 月的最後一周，美國有 5000 多名 Covid-19 住院患者，廣泛使用 MATH+ 方案可能意味著未來幾個月將增加數千名幸存者。截至 2020 年 12 月 18 日，報告使用部分或全部 MATH+ 方案的醫生數量已經增長到 120 多名。

## 本文的結論是：

"...COVID-19 中發現的多種病理生理機製可能需要多種治療藥物協同作用，以抵消這種異常免疫反應的多種有害後果。要找到一顆“靈丹妙藥”，甚至一種能在疾病的多個階段都有效的藥物，都是極其不可能的。Math+ 治療方案提供了一種廉價的，安全性眾所周知的藥物組合，這種基於強大的生理學原理和不斷增加的臨床證據基礎，潛在地為 COVID-19 患者的管理提供了一種挽救生命的方法。”

能在醫院裏存活下來說明治療效果不錯，但如果身體健康到不需要住院治療就更好了。

FLCCC 聯盟開發了用於門診護理的 I-MASK 協議。10 月，伊維菌素藥物加入住院 (MATH+) 和門診 (I-MASK) 方案。伊維菌素是一種廉價、廣泛使用的藥物，因其抗寄生蟲作用獲得 2015 年諾貝爾生理學或醫學獎。它似乎也是一種有效的抗病毒藥物。

這項研究增加了數十份出版物的數量，包括兩項與維生素 D 有關的前瞻性隨機對照試驗，將充足的維生素 D、鋅、維生素 C 和/或硒蛋白更好的聯合起來用於對抗 Covid-19。

## SARS-CoV-2 大流行的發現和警示:

1. 抗壞血酸在對抗已知和未知的傳染性病原體時是非常有效的。這一點自 20 世紀 40 年代以來就已經為人所知。Marik 博士最近的工作幫助擴大我們對抗炎和內皮細胞(血管)來自抗壞血酸和皮質醇共同增效作用起到的治療效果的理解。

- a. 嚴重的 Covid-19 疾病威脅生命的三個最主要方面是高炎癥、高凝和嚴重缺氧。抗壞血酸對免疫細胞、內皮細胞和氣道組織的作用有助於緩解這三個問題。
- b. 在重症監護中，靜脈注射皮質醇和抗壞血酸可在幾分鐘內開始逆轉糖蛋白質復合物和內皮細胞損傷。
- c. 定時、定量給藥維持一個穩定的狀態會更好，因為抗壞血酸的半衰期短，早期幹預效果更好，因為白細胞的激活需要依賴高水平的抗壞血酸。在生病期間，每餐服用數克，增加攝入量對抗腸道耐受性是有幫助的。生病的時候，一整天都要服用抗壞血酸，一次攝入的量遠遠不夠。

約瑟夫·瓦倫醫生已經連續工作 270 天了。他和他的團隊使用 MATH+ 方案，發現 95% 的 Covid-19 患者都能存活。

2. 營養不是單獨起作用的;測試單一營養成分效果的觀察性和/或幹預性研究可能會忽略最佳效益和準確評估所需的混雜因素和協同增效作用。

3. 維持血液濃度 40 - 80 ng/mL 的維生素 D 水平是優化免疫健康的一個主要部分。

a. 維生素 D 是一種強大的激素，影響著 3000 多個基因的表達和功能，是先天和適應性免疫系統的主要組成部分。威爾·泰勒博士已經證明了其中的兩個基因，TRXND1 和 GCLC，在 SARS-Cov-2 感染時成為一個重要的部位。他已經證明，病毒抑製和重要的抗氧化劑、DNA 合成調節因子、鐵衰竭和內質網應激相關的基因 (TXNRD1, TXNRD3, GCLC, GPX4, SELENOF, SELENOK, SELENOM, SELENOS) 的表達，而維生素 D 顯著上調其中兩個基因:TXNRD1 和 GCLC 的表達。

b. 對非工業化國家健康部落人口的研究表明，血液維生素 D 水平為 40 ng/mL。

c. 1903 年，尼爾斯·裏伯格·芬森 (Niels Ryberg Finsen) 獲得了諾貝爾生理學和醫學獎，“以表彰他在治療疾病方面的貢獻……通過集中光輻射，他為醫學開辟了一條新途徑”。

d. 維生素 D 不足和缺乏和不斷增加的心血管病的死亡、ICU 死亡和 Covid-19 死亡的風險相關。

- e. 鎂是維生素 D 代謝的重要輔助因子(也是生物活性 ATP 的重要輔助因子)。
  - f. 平衡 D3 與維生素 K2 的攝入對最佳的鈣代謝和分布很重要。125-250 mcg (5,000-10,000 IU) D3 與 100 mcg K2 MK7 的比值是有益的。
  - g. 腎臟疾病嚴重損害 D3 和硒蛋白代謝。
4. 在人類生物化學中，維生素 D 和硒的聯系非常緊密。
- a. Schutze 博士等人在 1999 年發表的文章指出，需要足量的硒才能幫助維生素 D3 有效上調 TXNRD1 的表達。
  - b. 在人類，D3 和必需氨基酸硒半胱氨酸都必須有足夠的量才能有效地產生幾種硒蛋白。
  - c. 研究表明，與單獨補充 D3 相比，共同補充 D3 和 L-半胱氨酸可改善 GSH、CYP24A1 和維生素 D 調節基因的狀態，包括上調 PGC -1 $\alpha$ 、NRF2 和 GLUT-4 基因表達。
  - d. 反過來，谷胱甘肽增加了維生素 D 的循環，增強了維生素 D 的作用。
5. 維生素 D 和硒蛋白是免疫記憶細胞的形成和維持所必需的。不足不僅會增加感染性疾病的風險，也會影響對感染適應性免疫的長久益處。這也可能暗示了對疫苗接種成功的可能性。

6. 在一般人群中，硒濃度為 70 - 150 ng/mL 時可以表現出好的健康狀況。血中硒蛋白 P 水平為 4.3 +/- 1.0 mg/L 時有助於 Covid-19 患者預後的改善;將 Zn 和 SELENOP 維持在參考範圍內顯示生存率高。

7. 微生物理論是有幫助的，但宿主體質仍然是很重要的。營養不足仍然是全球和國家公共衛生的頭號敵人。

a. 宿主因素影響許多病毒的致病性。許多影響宿主的因素是可以改變的，並且與營養有關。

b. 當一些病毒在營養不良的環境中複製時，特別是在缺乏硒的環境中，它們會變異成更有害的毒株。“次級營養不良”是一個未受重視的概念。只要人們營養不良，就有可能繼續出現更致命的毒株，而這又使營養不良的人面臨病毒突變的風險。

c. 對抗感染會大大增加人體的代謝需求。病毒也需要營養;宿營養和必需蛋白質的竊取和/或破壞進一步影響了人們為消除感染，恢復健康所需要的額外營養。

d.

(Michael Passwater 是美國臨床病理學協會認證的醫學技術專家，免疫血液學專家，實驗室管理文憑。他在臨床實驗室工作了 28 年，獲得了特拉華大學醫學技術學士學位。作為理查德·帕斯沃特 (Richard Passwater) 博士的兒子，他從出生前就開始服用維生素 C 和其他營養補充劑。)

## References

1. Front Line Covid-19 Critical Care Alliance <https://covid19criticalcare.com>
2. Kory P, Meduri GU, Iglesias J, Varon J, Marik PE. Clinical and Scientific Rationale for the "MATH+" Hospital Treatment Protocol for COVID-19. Journal of Intensive Care Medicine. <https://doi.org/10.1177/0885066620973585>
3. FLCC Alliance (2020) I-MASK+ Protocol. <https://hardball.parkoffletter.org/wp-content/uploads/2020/12/FLCCC-I-MASK-Protocol-v6-2020-12-09-ENGLISH.pdf>
4. The Nobel Prize in Physiology or Medicine 2015. NobelPrize.org. Nobel Media AB 2020. <https://www.nobelprize.org/prizes/medicine/2015/summary>
5. Tay MYF, Fraser JE, Chan WKK, et al. (2013) Nuclear localization of dengue virus (DENV) 1-4 non-structural protein 5; protection against all 4 DENV serotypes by the inhibitor Ivermectin. Antiviral Research. 99:301-306. <https://pubmed.ncbi.nlm.nih.gov/23769930>
6. Varghese FS, Kaukinen P, Gläsker S, et al. (2016) Discovery of berberine, abamectin and ivermectin as antivirals against chikungunya and other alphaviruses. Antiviral Research. 126:117-124. <https://pubmed.ncbi.nlm.nih.gov/26752081>
7. Wagstaff KM, Sivakumaran H, Heaton SM, et al. (2012) Ivermectin is a specific inhibitor of importin alpha/beta-mediated nuclear import able to inhibit replication of HIV-1 and dengue virus. Biochemical Journal. 443:851-856. <https://pubmed.ncbi.nlm.nih.gov/22417684>



8. King CR, Tessier TM, Dodge MJ, et al. (2020) Inhibition of Human Adenovirus Replication by the Importin alpha/beta1 Nuclear Import Inhibitor Ivermectin. *Journal of Virology*. 94:e00710-20. <https://pubmed.ncbi.nlm.nih.gov/32641484>
9. Caly L, Druce JD, Catton MG, et al. (2020) The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. *Antiviral Res.* 178:104787. <https://pubmed.ncbi.nlm.nih.gov/32251768>
10. Kaufman HW, Niles JK, Kroll MH, Bi C, Holick MF (2020) SARS-CoV-2 positivity rates associated with circulating 25-hydroxyvitamin D levels. *PLoS ONE* 15:e0239252. <https://doi.org/10.1371/journal.pone.0239252>
11. Mercola J, Grant WB, Wagner CL. (2020) Evidence Regarding Vitamin D and Risk of COVID-19 and Its Severity. *Nutrients*, 12:3361. <https://www.mdpi.com/2072-6643/12/11/3361>
12. Zhang J, Taylor EW, Bennett K, Saad R, Rayman MP. (2020) Association between regional selenium status and reported outcome of COVID-19 cases in China. *Am J Clin Nutr*, 111:1297-1299. <https://doi.org/10.1093/ajcn/nqaa095>
13. Moghaddam A, Heller RA, Sun Q, et al. (2020) Selenium deficiency is associated with mortality risk from COVID-19. *Nutrients* 12:2098. <https://doi.org/10.3390/nu12072098>
14. Heller RA, Sun Q, Hackler J et al. (2021) Prediction of survival odds in COVID-19 by zinc, age, and selenoprotein P as composite biomarker. *Redox Biology* 38:101764. Online ahead of print. <https://pubmed.ncbi.nlm.nih.gov/33126054>

15. Merzon E. (2020) Low plasma 25(OH) vitamin D level is associated with increased risk of COVID-19 infection: an Israeli population-based study. FEBS J. 287:3693-3702. <https://pubmed.ncbi.nlm.nih.gov/32700398>
16. Castillo ME, Costa LME, Barrios JMV, et al. (2020) Effect of calcifediol treatment and best available therapy versus best available therapy on intensive care unit admission and mortality among patients hospitalized for COVID-19: A pilot randomized clinical study. J Steroid Biochem Mol Biol 203:105757. <https://pubmed.ncbi.nlm.nih.gov/32871238>
17. Jungreis I, Kellis M. (2020) Mathematical analysis of Cordoba calcifediol trial suggest strong role for vitamin D in reducing ICU admissions of hospitalized COVID-19 patients. MedRxiv preprint. <https://doi.org/10.1101/2020.11.08.20222638>
18. Grassroots Health Nutrient Research Institute. <https://www.grassrootshealth.net>
19. Polonikov, A. (2020) Endogenous deficiency of glutathione as the most likely cause of serious manifestations and death in COVID-19 patients. ACS Infect Dis 2020, 6, 7, 1558-1562. <https://doi.org/10.1021/acsinfecdis.0c00288>
20. Horowitz RI, Freeman PR, Bruzzese J. (2020) Efficacy of glutathione therapy in relieving dyspnea associated with COVID-19 pneumonia: A report of 2 cases. Respir Med Case Rep 2020, 101063. <https://doi.org/10.1016/j.rmcr.2020.101063>

21. Zhao B, Fei J, Chen Y, et al. (2014) Vitamin C treatment attenuates hemorrhagic shock related multi-organ injuries through the induction of heme oxygenase-1. BMC Complementary and Alternative Medicine 2014, 14:442-454. <https://pubmed.ncbi.nlm.nih.gov/25387896>
22. Oudemans-van Straaten HM, Spoelstra-de Man AME, de Waard MC. (2014) Vitamin C revisited. Critical Care 18:460-473. <https://pubmed.ncbi.nlm.nih.gov/25185110>
23. Fowler AA, Syed AA, Knowlson S, Natarajan R, et al. (2014) Phase I Safety trial of intravenous ascorbic acid in patients with severe sepsis. Journal of Translational Medicine, 12:32. <https://pubmed.ncbi.nlm.nih.gov/24484547>
24. Gu W, Cheng A, Barnes H, Kuhn B, Schivo M. (2014) Vitamin C Deficiency Leading to Hemodynamically Significant Bleeding. JSM Clinical Case Reports. 2:1046. <http://www.jscimedcentral.com/CaseReports/casereports-2-1046.pdf>
25. Manning J, Mitchell B, Appaduras DA, May JM, et al. (2013) Vitamin C Promotes Maturation of T-Cells. Antioxid Redox Signal. 19:2054-2067. <https://pubmed.ncbi.nlm.nih.gov/23249337>
26. Ladumer A, Schmitt CA, Schachner D, et al. (2012) Ascorbate stimulates endothelial nitric oxide synthase enzyme activity by rapid modulation of its phosphorylation status. Free Radic Biol Med. 2012 May 15; 52:2082-2090. <https://pubmed.ncbi.nlm.nih.gov/22542797>
27. Reddell L, Cotton BA. (2012) Antioxidant and micronutrient supplementation in trauma patients. Curr Opin Clin Nutr Metab Care. 15:181-187. <https://pubmed.ncbi.nlm.nih.gov/22261953>

28. May JM, Qu ZC. (2010) Ascorbic Acid Prevents Increased Endothelial Permeability Caused by Oxidized Low Density Lipoprotein. *Free Radical Res.* 44:1359-1368. <https://pubmed.ncbi.nlm.nih.gov/20815791>
29. Duconge J, Miranda-Massari JR, Gonzalez MJ, et al. (2008) Pharmacokinetics of vitamin C: insights into the oral and intravenous administration of ascorbate. *P R Health Sci J.* 27:7-19. <http://prhsj.rcm.upr.edu/index.php/prhsj/article/view/13>
30. Deicher R, Ziai F, Begknayer C, et al. (2005) Low Total Vitamin C Plasma Level Is a Risk Factor for Cardiovascular Morbidity and Mortality in Hemodialysis Patients. *J Am Soc Nephrol.* 16:1811-1818. <https://pubmed.ncbi.nlm.nih.gov/15814831>
31. Heller R, Munscher-Paulig F, Grabner R, Till V. (1999) L-Ascorbic Acid Potentiates Nitric Oxide Synthesis in Endothelial Cells. *J Biol Chem,* 274:8254-8260. <https://pubmed.ncbi.nlm.nih.gov/10075731>
32. Leibovitz B, Siegel BV. (1978) Ascorbic acid, neutrophil function, and the immune response. *Int J Vitam Nutr Res.* 48:159-164. <https://pubmed.ncbi.nlm.nih.gov/357320>
33. Klenner FR. (1971) Observations on the Dose and Administration of Ascorbic Acid When Employed Beyond the Range of a Vitamin in Human Pathology. *J Applied Nutrition,* 1971, Vol 23:61-87. [https://jeffreydachmd.com/wp-content/uploads/2013/07/Ascorbic\\_Acid\\_Fred\\_klenner\\_1971.pdf](https://jeffreydachmd.com/wp-content/uploads/2013/07/Ascorbic_Acid_Fred_klenner_1971.pdf)

34. Lee RE. (1961) Ascorbic Acid and the Peripheral Vascular System. *Ann N Y Acad Sci.* 92:295-301. <https://pubmed.ncbi.nlm.nih.gov/13760268>
35. Lee RE, Holze EA. (1951) Nutritional factors in hemodynamics: dissociation of pressor response and hemorrhage resistance in avitaminosis C. *Proc Soc Exp. Biol Med.* 76:325-329. <https://pubmed.ncbi.nlm.nih.gov/14827915>
36. McCormick WJ. (1951) Vitamin C in the Prophylaxis and Therapy of Infectious Diseases. *Arch Pediatr*, 68:1-9.
37. Klenner FR. (1949) The Treatment of Poliomyelitis and Other Virus Diseases with Vitamin C. *Journal of Southern Medicine and Surgery*, 111:209-214. <https://pubmed.ncbi.nlm.nih.gov/18147027> [https://www.seanet.com/~alexs/ascorbate/194x/klenner-fr-southern\\_med\\_surg-1949-v111-n7-p209.htm](https://www.seanet.com/~alexs/ascorbate/194x/klenner-fr-southern_med_surg-1949-v111-n7-p209.htm)
38. Klenner FR. (19448) Virus Pneumonia and its Treatment with Vitamin C. *Journal of Southern Medicine and Surgery*, 110:36-38. <https://pubmed.ncbi.nlm.nih.gov/18900646>[https://www.mv.helsinki.fi/home/hemila/CP/Klenner\\_1948\\_ch.pdf](https://www.mv.helsinki.fi/home/hemila/CP/Klenner_1948_ch.pdf)
39. Lee RE, Lee NZ. (1947) The peripheral vascular system and its reactions in scurvy; an experimental study. *Am J Physiol*, 149:465-475. <https://pubmed.ncbi.nlm.nih.gov/20239975>
40. Jungeblut CW. (1935) Inactivation of Poliomyelitis Virus in vitro by Crystalline Vitamin C (Ascorbic Acid). *J Exp Med*, 62:517-521. <https://pubmed.ncbi.nlm.nih.gov/19870431>

41. Colunga Biancatelli RM, Berrill M, Catravas JD, Marik PE. (2020) Quercetin and Vitamin C: An experimental, synergistic therapy for the prevention and treatment of SARS-CoV-2 related disease (COVID-19). *Front Immunol*, 11:1451. <https://pubmed.ncbi.nlm.nih.gov/32636851>
42. Colunga Biancatelli RM, Berrill M, Marik PE. (2020) The antiviral properties of vitamin C. *Expert Rev Anti Infect Ther*, 18:99-101. <https://pubmed.ncbi.nlm.nih.gov/31852327>
43. Barabutis N, Khangoora V, Marik PE, Catravas JD. (2017) Hydrocortisone and Ascorbic Acid synergistically protect and repair lipopolysaccharide-induced pulmonary endothelial barrier dysfunction. *Chest*, 152:954-962. <https://pubmed.ncbi.nlm.nih.gov/28739448>
44. de Melo AF, Homem-de-Mello M. (2020) High-dose intravenous vitamin C may help in cytokine storm in severe SARS-CoV-2 infection. *Crit Care*, 24:500. <https://pubmed.ncbi.nlm.nih.gov/32792018>
45. Marik PE. (2018) Hydrocortisone, Ascorbic Acid and Thiamine (HAT therapy) for the treatment of sepsis. Focus on ascorbic acid. *Nutrients*, 10:1762. <https://pubmed.ncbi.nlm.nih.gov/30441816>
45. May JM, Qu ZC. (2011) Ascorbic acid prevents oxidant-induced increases in endothelial permeability. *Biofactors*, 37:46-50. <https://pubmed.ncbi.nlm.nih.gov/21328627>
46. Utoguchi N, Ikeda K, Saeki K et al. (1995) Ascorbic acid stimulates barrier function of cultured endothelial cell monolayer. *J Cell Physiol*, 163:393-399. <https://pubmed.ncbi.nlm.nih.gov/7706381>

47. Han M, Pendem S, Teh SL, Sukumaran DK, Wu F, Wilson JX. (2010) Ascorbate protects endothelial barrier function during septic insult: Role of protein phosphatase type 2A. *Free Radic Biol Med* 2010; 48:128-35. <https://pubmed.ncbi.nlm.nih.gov/19840845>
48. Khan HMW, Parikh N, Megah SM, Predeteanu GS. (2020) Unusual Early Recovery of a Critical COVID-19 After Administration of Intravenous Vitamin C. *Am J Case Rep*, 21:e925521 <https://pubmed.ncbi.nlm.nih.gov/32709838>
49. Bharara A, Grossman C, Grinnon D, et al. (2016) Intravenous Vitamin C Administered as Adjunctive Therapy for Recurrent Acute Respiratory Distress Syndrome. *Case Rep Crit Care*. 2016;8560871. <https://pubmed.ncbi.nlm.nih.gov/27891260>
50. May JM, Harrison FE. (2013) Role of Vitamin C in the Function of the Vascular Endothelium. *Antioxid Redox Signal*. 19:2068-2083. <https://pubmed.ncbi.nlm.nih.gov/23581713>
51. Marik PE, Khangoora V, Rivera R, et al. (2017) Hydrocortisone, Vitamin C, and Thiamine for the Treatment of Severe Sepsis and Septic Shock: A Retrospective Before-After Study. *Chest*, 151:1229-1238. <https://pubmed.ncbi.nlm.nih.gov/27940189>
52. Barabutis N, Khangoora V, Marik PE, Catravas JD. (2017) Hydrocortisone and Ascorbic Acid Synergistically Prevent and Repair Lipopolysaccharide-Induced Pulmonary Endothelial Barrier Dysfunction. *Chest*, 152:954-962. <https://pubmed.ncbi.nlm.nih.gov/28739448>

53. Parker WH, Rhea EM, Qu ZC, Hecker MR, May JM. (2016) Intracellular ascorbate tightens the endothelial permeability barrier through Epac1 and the tubulin cytoskeleton. *Am J Physiol Cell Physiol.* 311:C652-C662. <https://pubmed.ncbi.nlm.nih.gov/27605450>
54. Ferry M, Coley N, Andrieu S, et al. (2013) How to design nutritional intervention trials to populations and apply for efficacy claims: a statement from the international academy on nutrition and aging task force. *J Nutr Heal Aging.* 17:619-523. <https://pubmed.ncbi.nlm.nih.gov/23933873>
55. Bieri JG. (1964) Synergistic effects between antioxidants and selenium or vitamin E. *Biochem Pharmacol.* 13:1465-1470. <https://pubmed.ncbi.nlm.nih.gov/14239620>
56. Badmaev V, Majeed M, Passwater RA. (1996) Selenium: A Quest for Better Understanding. *Altern Ther Health Med.* 2:59-62, 65-67. <https://pubmed.ncbi.nlm.nih.gov/8795924>
57. Taylor, E.W. RNA viruses vs. DNA synthesis: a general viral strategy that may contribute to the protective antiviral effects of selenium. Preprints 2020, 10.20944/preprints202006.0069.v1, 2020060069, <http://doi.org/10.20944/preprints202006.0069.v1>
58. Luxwolda MF, Kuipers RS, Kema IP, Dijck-Brouwer DA, Muskiet FA. (2012) Traditionally living populations in East Africa have a mean serum 25-hydroxyvitamin D concentration of 115 nmol/l. *Br J Nutr.* 108:1557-1561. <https://pubmed.ncbi.nlm.nih.gov/22264449>
59. The Nobel Prize in Physiology or Medicine 1903. NobelPrize.org. Nobel Media AB 2020. <https://www.nobelprize.org/prizes/medicine/1903/summary>
60. Dean C (2017) *The Magnesium Miracle*, 2nd Ed. Ballantine Books. ISBN-13 : 978-0399594441



61. Deng X, Song Y, Manson JE, et al. (2013) Magnesium, vitamin D status and mortality: results from US National Health and Nutrition Examination Survey (NHANES) 2001 to 2006 and NHANES III. BMC Med, 11:187. <https://pubmed.ncbi.nlm.nih.gov/23981518>
62. Flore R, Ponziani FR, Di Rienzo TA, et al. (2013) Something more to say about calcium homeostasis: the role of vitamin K2 in vascular calcification and osteoporosis. Eur Rev Med Pharmacol Sci. 17:2433-2440. <https://pubmed.ncbi.nlm.nih.gov/24089220>
63. Schwalfenberg GK. (2017) Vitamins K1 and K2: The Emerging Group of Vitamins Required for Human Health. J Nutr Metab. 2017:6254836. <https://pubmed.ncbi.nlm.nih.gov/28698808>
64. Bosworth C, de Boer IH. (2013) Impaired vitamin D metabolism in CKD. Semin Nephrol. 33:158-168. <https://pubmed.ncbi.nlm.nih.gov/23465502>
65. Reinhardt W, Dolff S, Benson S, et al. (2015) Chronic Kidney Disease Distinctly Affects Relationship Between Selenoprotein P Status and Serum Thyroid Hormone Parameters. Thyroid. 25:1091-1096. <https://pubmed.ncbi.nlm.nih.gov/26348725>
66. Schütze N, Fritsche J, Ebert-Dumig R, et al. (1999) The selenoprotein thioredoxin reductase is expressed in peripheral blood monocytes and THP1 human myeloid leukemia cells--regulation by 1,25-dihydroxyvitamin D3 and selenite. Biofactors, 10:329-338, <https://pubmed.ncbi.nlm.nih.gov/10619700>
67. Jain SK, Micinski D. (2013) Vitamin D upregulates glutamate cysteine ligase and glutathione reductase, and GSH formation, and decreases ROS and MCP-1 and IL-8 secretion in high-glucose

exposed U937 monocytes. *Biochem Biophys Res Commun* 437:7-

11, <https://pubmed.ncbi.nlm.nih.gov/23770363>

68. Alvarez JA, Chowdhury R, Jones DP, et al. (2014) Vitamin D status is independently associated with plasma glutathione and cysteine thiol/disulphide redox status in adults. *Clin Endocrinol (Oxf)*

81:458-466. <https://pubmed.ncbi.nlm.nih.gov/24628365>

69. Parsanathan R, Jain SK. (2019) Glutathione deficiency induces epigenetic alterations of vitamin D metabolism genes in the livers of high-fat diet-fed obese mice. *Sci Rep*.

9:14784. <https://pubmed.ncbi.nlm.nih.gov/31616013>

70. Fan YG, Pang ZQ, Wu TY, et al. (2020) Vitamin D deficiency exacerbates Alzheimer-like pathologies by reducing antioxidant capacity. *Free Radic Biol Med*. 161:139-

149. <https://pubmed.ncbi.nlm.nih.gov/33068737>

71. Jain SK, Parsanathan R, Achari AE, et al. (2017) Glutathione Stimulates Vitamin D Regulatory and Glucose Metabolism Genes, Lowers Oxidative Stress and Inflammation, and Increases 25-Hydroxy-Vitamin D Levels in Blood: A Novel Approach to Treat 25-Hydroxyvitamin D Deficiency.

*Antioxid Redox Signal*. 29:1792-1807. <https://pubmed.ncbi.nlm.nih.gov/30160165>

72. Guillin OM, Vindry C, Ohlmann T, Chavatte L. (2019) Selenium, Selenoproteins, and Viral Infection. *Nutrients*, 11:2101. <https://doi.org/10.3390/null092101>

73. Huang Z, Rose AH, Hoffman PR. (2012) The Role of Selenium in Inflammation and Immunity: From Molecular Mechanisms to Therapeutic Opportunities. *Antioxid Redox Signal*. 16:705-743. <https://pubmed.ncbi.nlm.nih.gov/21955027>
74. Cantorna MT, Snyder L, Lin YOD, Yang L. (2015) Vitamin D and 1,25(OH)<sub>2</sub>D Regulation of T cells. *Nutrients*, 7:3011-3021. <https://pubmed.ncbi.nlm.nih.gov/25912039>
75. Looman KIM, Jansen MAE, Voortman T, et al. (2017) The role of vitamin D on circulating memory T cells in children: The generation R Study. *Pediatr. Allergy Immunol*. 28:579-587. <https://pubmed.ncbi.nlm.nih.gov/28686349>
76. Taylor EW, Radding W. (2020) Understanding Selenium and Glutathione as Antiviral Factors in COVID-19: Does the Viral M<sub>1</sub> pro Protease Target Host Selenoproteins and Glutathione Synthesis? *Front Nutr* 7:143. <https://pubmed.ncbi.nlm.nih.gov/32984400>
77. Bellinger FP, Ramoy AV, Reeves MA, Berry MJ. (2009) Regulation and function of selenoproteins in human disease. *Biochem J*, 422:11-22. <https://pubmed.ncbi.nlm.nih.gov/19627257>
78. Hiffler L, Rakotoambinina B. (2020) Selenium and RNA viruses interactions: Potential implications for SARS-CoV-2 infection (COVID-19). *Front Nutr*. 7:164. <https://pubmed.ncbi.nlm.nih.gov/33015130>
79. Beck MA, Levander OA, Handy J. (2003) Selenium deficiency and viral infection. *J Nutr*. 133(5 Suppl 1):1463S-1467S. <https://pubmed.ncbi.nlm.nih.gov/12730444>

80. Cunningham-Rundles S, McNeeley DF, Moon A.(2005) Mechanisms of nutrient modulation of the immune response. J Allergy Clin Immunol. 115:1119-1128; quiz

1129. <https://pubmed.ncbi.nlm.nih.gov/15940121>

81. Hoffmann PR, Berry MJ. (2008) The influence of selenium on immune responses. Mol Nutr Food Res. 52:1273-1280. <https://pubmed.ncbi.nlm.nih.gov/18384097>

82. Taylor AK, Cao W, Vora KP, et al. (2013) Protein energy malnutrition decreases immunity and increases susceptibility to influenza infection in mice. J Infect Dis. 207:501-

510. <https://pubmed.ncbi.nlm.nih.gov/22949306>

83. Beck MA, Handy J, Levander OA. (2004) Host nutritional status: the neglected virulence factor. Trends Microbiol, 12:417-423. <https://pubmed.ncbi.nlm.nih.gov/15337163>

84. Harthill M. (2011) Review: micronutrient selenium deficiency influences evolution of some viral infectious diseases. Biol Trace Elem Res. 143:1325-

1336. <https://pubmed.ncbi.nlm.nih.gov/21318622>

85. Mak TW, Grusdat M, Duncan GS, et al. (2017) Glutathione Primes T cell Metabolism for Inflammation. Immunity. 46:675-689, 1089-

1090. <https://pubmed.ncbi.nlm.nih.gov/28423341>, <https://pubmed.ncbi.nlm.nih.gov/28636957>

86. Leibovitz B, Siegel BV. (1978) Ascorbic acid, neutrophil function, and the immune response. Int J Vitam Nutr Res. 48:159-164. <https://pubmed.ncbi.nlm.nih.gov/357320>

87. Manning J, Mitchell B, Appadurai DA, et al. (2013) Vitamin C Promotes Maturation of T-Cells.

Antioxid Redox Signal. 19:2054-2067. <https://pubmed.ncbi.nlm.nih.gov/23249337>

### **Nutritional Medicine is Orthomolecular Medicine**

Orthomolecular medicine uses safe, effective nutritional therapy to fight illness. For more

information: <http://www.orthomolecular.org>

### **Find a Doctor**

To locate an orthomolecular physician near

you: <http://orthomolecular.org/resources/omns/v06n09.shtml>

The peer-reviewed Orthomolecular Medicine News Service is a non-profit and non-commercial informational resource.

### **Editorial Review Board:**

Seth Ayettey, M.B., Ch.B., Ph.D. (Ghana)

Ilyès Baghli, M.D. (Algeria)

Ian Brighthope, MBBS, FACNEM (Australia)

Gilbert Henri Crussol, D.M.D. (Spain)

Carolyn Dean, M.D., N.D. (USA)

Ian Dettman, Ph.D. (Australia)

Damien Downing, M.B.B.S., M.R.S.B. (United Kingdom)

Ron Erlich, B.D.S. (Australia)

Hugo Galindo, M.D. (Colombia)

Martin P. Gallagher, M.D., D.C. (USA)

Michael J. Gonzalez, N.M.D., D.Sc., Ph.D. (Puerto Rico)

William B. Grant, Ph.D. (USA)

Claus Hancke, MD, FACAM (Denmark)

Tonya S. Heyman, M.D. (USA)

Suzanne Humphries, M.D. (USA)

Ron Hunninghake, M.D. (USA)

Bo H. Jonsson, M.D., Ph.D. (Sweden)

Felix I. D. Konotey-Ahulu, MD, FRCP, DTMH (Ghana)

Jeffrey J. Kotulski, D.O. (USA)

Peter H. Lauda, M.D. (Austria)

Thomas Levy, M.D., J.D. (USA)

Alan Lien, Ph.D. (Taiwan)

Homer Lim, M.D. (Philippines)

Stuart Lindsey, Pharm.D. (USA)

Victor A. Marcial-Vega, M.D. (Puerto Rico)

Charles C. Mary, Jr., M.D. (USA)

Mignonne Mary, M.D. (USA)

Jun Matsuyama, M.D., Ph.D. (Japan)

Joseph Mercola, D.O. (USA)

Jorge R. Miranda-Massari, Pharm.D. (Puerto Rico)

Karin Munsterhjelm-Ahumada, M.D. (Finland)

Tahar Naili, M.D. (Algeria)

W. Todd Penberthy, Ph.D. (USA)

Selvam Rengasamy, MBBS, FRCOG (Malaysia)

Jeffrey A. Ruterbusch, D.O. (USA)

Gert E. Schuitemaker, Ph.D. (Netherlands)

T.E. Gabriel Stewart, M.B.B.CH. (Ireland)

Thomas L. Taxman, M.D. (USA)

Jagan Nathan Vamanan, M.D. (India)

Garry Vickar, M.D. (USA)

Ken Walker, M.D. (Canada)

Raymond Yuen, MBBS, MMed (Singapore)

Anne Zauderer, D.C. (USA)

**Andrew W. Saul, Ph.D. (USA), Editor-In-Chief**

Associate Editor: Robert G. Smith, Ph.D. (USA)

Editor, Japanese Edition: Atsuo Yanagisawa, M.D., Ph.D. (Japan)

Editor, Chinese Edition: Richard Cheng, M.D., Ph.D. (USA)

Editor, French Edition: Vladimir Arianoff, M.D. (Belgium)

Editor, Norwegian Edition: Dag Viljen Poleszynski, Ph.D. (Norway)

Editor, Arabic Edition: Moustafa Kamel, R.Ph, P.G.C.M (Egypt)

Editor, Korean Edition: Hyoungjoo Shin, M.D. (South Korea)

Assistant Editor: Helen Saul Case, M.S. (USA)

Technology Editor: Michael S. Stewart, B.Sc.C.S. (USA)

Legal Consultant: Jason M. Saul, JD (USA)

**Comments and media contact:** [drsaul@doctoryourself.com](mailto:drsaul@doctoryourself.com) OMNS welcomes but is unable to respond to individual reader emails. Reader comments become the property of OMNS and may or may not be used for publication.

**To Subscribe at no charge:** <http://www.orthomolecular.org/subscribe.html>

**To Unsubscribe from this list:** <http://www.orthomolecular.org/unsubscribe.html>



